32 results about "Phosphorylethanolamine" patented technology

The invention discloses an attenuated salmonella typhimurium EN-VNP (Enhanced Natriuretic Peptide) strain as well as a preparation method and application of the attenuated salmonella typhimurium EN-VNP strain. Comprising the following steps: on the basis of a salmonella VNP20009 strain, flagellin genes fliC and fljB, a phosphoethanolamine transferase gene eptA, a 4-amino-4-deoxy-L-arabinose transferase gene arnT and phosphotransferase yeiU are sequentially knocked out or silenced, and a strain is formed after a phosphotransferase gene lpxE is knocked in or overexpressed, so that the attenuated salmonella typhimurium EN-VNP strain is prepared. According to the attenuated salmonella typhimurium EN-VNP with low toxicity and the T cell adjuvant effect and an EN-OMV antigen delivery system prepared from the attenuated salmonella typhimurium EN-VNP, an improved strain does not contain flagellin, an LPS molecular structure is changed, the attenuated salmonella typhimurium EN-VNP has the low toxicity and the T cell adjuvant effect, and normal multiplication culture can be achieved.

The invention relates to a bionic exosome for anti-inflammation and repair as well as a preparation method and application thereof, and belongs to the field of cosmetics. The bionic exosome provided by the invention comprises a membrane structure and an internal load phase, the membrane structure comprises a phospholipid bilayer, a stabilizer and a targeting ligand; the internal load phase comprises a solvent and an active component; the phospholipid bilayer is composed of phospholipid compounds; preferably, at least one of the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and the 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine is adopted as the phospholipid compound, and at least one of the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and the 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine is adopted as the phospholipid compound; at least one of cholesterol, phytosphingosine and sodium stearoyl glutamate is preferably adopted as a stabilizer, so that the stabilizer of the obtained bionic exosome is improved, and the bionic exosome has the advantages of high encapsulation efficiency, good encapsulation efficiency stability, simplicity in operation, excellent anti-inflammatory and repairing effects and the like.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a cell membrane protein fusion lipidosome and a preparation method and application thereof.The cell membrane protein fusion lipidosome is prepared from dioleoyl lecithin, 1, 2-propylene glycol and 1, 3-propylene glycol according to the mass ratio of (3.17-7.17): (0.96-2.87): (0.86-2.57): (0.5-2.5): (0.5-2.5). The preparation method comprises the following steps of: adding 1, 2-distearoyl-sn-glycerol-3-phosphoethanolamine-N-[carboxyl (polyethylene glycol)-2000], cholesterol, triton X-100 and cell membrane protein; according to the cell membrane protein fusion liposome provided by the invention, the membrane protein loading rate is remarkably improved, and a technical support is provided for clinical application of a cell membrane material.

The invention discloses a salmonella typhimurium EN-VNP strain based on flagellin and LPS attenuation as well as a preparation method and application of the salmonella typhimurium EN-VNP strain, and particularly relates to the technical field of biology. The bacterial strain is formed by sequentially knocking out or silencing flagellin genes fliC and fljB, a phosphoethanolamine transferase gene eptA, a 4-amino-4-deoxy-L-arabinose transferase gene arnT and phosphotransferase yeiU on the basis of a salmonella VNP 20009 bacterial strain, and knocking in or overexpressing a phosphotransferase gene lpxE. The salmonella typhimurium EN-VNP strain disclosed by the invention has relatively high safety, the attenuated strain does not contain flagellin, and a lipid A molecule of LPS only retains one phosphate group, so that the safety of the strain is improved, and the strain is more suitable for serving as a vaccine and a drug delivery carrier.

The present invention discloses a recombinant Escherichia coli capable of efficiently producing monophospholipid A vaccine adjuvant, belonging to the fields of genetic engineering and synthetic biology. The present invention knocks out 132 genes related to membrane wall surface molecules, phospholipid and glucose transport, phosphoethanolamine modification and enoyl-ACP reductase in Escherichia coli MG1655, expresses lipid A modification genes FnlpxE, SepagP and SepagL, and constructs strain MW021 / pTEPL. The growth performance of MW021 / pTEPL is greatly improved and antibiotics and inducers are no longer required during the fermentation process; in a 2-L fermentation tank system, the highest OD of MW021 / pTEPL growth is 600 It can reach 38.54, and can produce 13.84g / L of dry cells and about 88.99mg / L of total lipid A; total lipid A contains only two structures, namely MPL and D-MPLA.

The present invention relates to an ophthalmological composition, comprising at least one nicotinic acetylcholine receptor (nAChR) modulator, in particular varenicline, mecamylamine and derivatives, and / or at least one substance of the endogenous Kennedy metabolic pathways, as well as salts and derivatives or pharmaceutically acceptable salts of these substances, and choline-containing phospholipids, salts and derivatives of these substances. From these groups, particular preference is given to choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (for example lecithin having a phosphatidylcholine content ≥ 80 wt.%, for example soy lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-α-glycerylphosphorylcholine, phosphatidylcholine, and phosphatidylethanolamine.

The invention relates to a flame-retardant skin-friendly polyurethane sponge with in-situ reaction and bio-enzyme catalysis synergism. The water-based polyurethane foam is prepared from the following components: polyether polyol, diphenylmethane diisocyanate or toluene diisocynate, a chain extender, a high-efficiency foam stabilizer, a high-efficiency composite catalyst, water and ethanolamine phosphate, ethanolamine phosphate is added into water in advance, and then all the raw materials are mixed for polymerization foaming; after curing, spraying a spraying liquid consisting of phosphoethanolamine, regenerated protein and transglutaminase to generate a nano protein film, and synchronously performing vacuum suction to keep sponge pores unblocked. The preparation method has the advantages that a small amount of ethanolamine phosphate is added before polymerization foaming to serve as a phosphorus-nitrogen synergistic flame retardant and also serve as a catalytic cross-linking agent to participate in a reaction during polymerization, biological enzyme is added for catalysis after curing is finished, and the skin-friendly PU sponge with excellent flame retardance is prepared through in-situ polymerization reaction and biological enzyme enzymatic polymerization cooperation, and the sponge performance is not affected; the raw materials of the flame retardant come from biomass products and are environment-friendly and safe.

The present invention relates to ophthalmic compositions comprising at least one substance of at least one nicotinic acetylcholine receptor (nAChR) modulator, in particular varenicline, megamine and derivatives thereof, and / or the endogenous Kennedy metabolic pathway, as well as salts and derivatives or pharmaceutically acceptable salts of these substances, and choline-containing phospholipids, salts and derivatives of these substances. From these groups, particularly preferred are choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (e.g. Lecithin having a phosphatidylcholine content of > = 80% by weight, e.g. Soybean lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-alpha-glycerophosphorylcholine, phosphatidylcholine, phosphatidylethanolamine.

A novel quantitative method, an enzyme for quantitative determination, a quantitative kit, and a quantitative sensor for quantitative determination of the concentration of EAP, which is a biomarker of depression, are provided. A quantitative method for quantifying phosphoethanolamine is provided, wherein an oxidoreductase is added to a sample containing phosphoethanolamine. A mediator can be reduced by adding the oxidoreductase, and the reduced mediator can be reacted with a reagent to determine the concentration of the phosphoethanolamine. Alternatively, as the oxidoreductase, hydrogen peroxide generated by adding an oxidase can be reacted with a reagent to determine the concentration of the phosphoethanolamine.

The invention relates to an exosome with high permeability and application of the exosome, and the surface of the exosome is connected with dioleoyl phosphatidylserine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylethanolamine and hirudin. The exosome constructed by the invention can improve the permeability of the skin, can carry active components to directly reach the skin epidermis and corium layer, is accumulated on the epidermis and corium layer, continuously provides nutrition for the skin, and fully exerts the skin care and beautifying effects.

The application discloses application of cell endogenous metabolites in preparation of medicines for treating and / or preventing aging. The cell endogenous metabolites are any one or combination of phosphocreatine, hypotaurine and / or phosphoethanolamine. The application finds that phosphocreatine, hypotaurine and phosphoethanolamine can effectively restore cell growth, reduce cell SA-beta-Gal staining intensity, improve cell mitochondrial function and increase ATP yield, restore cell mitochondrial membrane potential, alleviate damage caused by cell oxidative stress and premature aging, and also prolong the life of nematodes and restore exercise capacity in the middle of aging. Meanwhile, the three metabolites have a synergistic effect, and by adjusting the matching concentration of the three metabolites, the same cell protection effect can be achieved by mixed administration. Since the endogenous metabolites are accurate, efficient and safe, the three cell endogenous metabolites provided by the application can be used for preparing anti-aging medicines.

The invention discloses a strain of Chryseobacterium wanjuense C14, and a preparation method of the Chryseobacterium wanjuense C14. The invention further discloses application of the bacillus subtilis in inhibition of ralstonia solanacearum and application of the bacillus subtilis in degradation of straw. The Chryseobacterium sp. C14 can obviously inhibit the growth of pathogenic bacteria of tomato bacterial wilt, especially under the assistance of tomato rhizosphere metabolites such as O-phosphoethanolamine, mangiferin and L-tryptophan, the antibacterial effect of the Chryseobacterium sp. C14 is further enhanced, and the Chryseobacterium sp. C14 has higher environmental adaptability and prevention and treatment potential. The Chryseobacterium sp. C14 can also degrade protein, cellulose and hemicellulose at the same time, and can significantly promote the degradation of rice straw and corn straw. The Chryseobacterium sp. C14 has the functions of straw degradation and tomato ralstonia solanacearum inhibition, integrates a soil-borne disease biological control function and efficient straw degradation, and provides a green and efficient microbial new strategy for solving the problems of difficult straw treatment and difficult tomato bacterial wilt control in agricultural production.

The invention relates to a sample pretreatment method for pyrite elemental analysis. The method comprises the following steps: firstly, preparing a pretreatment agent: activating the surface of carboxymethyl chitosan by NHS / EDC, and then reacting with ethanolamine phosphate; secondly, a pyrite sample is taken and smashed into particles, the particles, NaOH, NaNO3 and a pretreatment agent are fully ground into powder, then the temperature is increased to 180-250 DEG C and then increased to 350-450 DEG C for heat preservation, sintered solids are transferred into a beaker, a hot nitric acid solution is added, the solids are dissolved through ultrasonic treatment, the solids are filtered into a volumetric flask after being cooled, and a to-be-tested sample is obtained after the volume is fixed through dilute nitric acid; according to the treatment method, use of a large amount of concentrated acid and perchloric acid is avoided, the reagent dosage is small, and environment friendliness is achieved; the recovery rate of 95% or above can be ensured when the treated sample is measured by instruments such as ICP-MS, the maximum RSD value does not exceed 5% compared with a standard value, and the accuracy is good.

The invention discloses a molecular marker related to the content of glyceryl phosphorylethanolamine in pig muscle and application of the molecular marker. The invention provides an application of a substance for detecting the genotype of an SNP site in a pig genome in at least one of the following applications: A1) detecting or assisting in detecting the content state of glyceryl phosphorylethanolamine of a to-be-detected pig; a2) breeding pigs with high content of glyceryl phosphorylethanolamine; a3) pig breeding; and A4) preparing a product for detection or auxiliary detection of the content state of the glyceryl phosphorylethanolamine of the to-be-detected pig. According to the invention, by detecting the genotype of the pig to be detected at the SNP site, early selection of the content of glyceryl phosphoryl ethanolamine in pig muscle can be realized, the production cost can be saved, the genetic progress can be accelerated, and the SNP site has great economic application value and scientific research value.

The present invention relates to ophthalmic compositions comprising at least one nicotinic acetylcholine receptor (nAChR) modulator, particularly varenicline, mecamillamine, and derivatives, and / or at least one substance of the endogenous Kennedy metabolic pathway, as well as salts and derivatives or pharmaceutically acceptable salts thereof, and choline-containing phospholipids, salts and derivatives thereof. Of these, choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (e.g., lecithin with a phosphatidylcholine content of 80% by weight or more, e.g., soy lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-α-glycerylphosphorylcholine, phosphatidylcholine, and phosphatidylethanolamine are particularly preferred.

The application relates to a sample pretreatment method for pyrite element analysis. First, a pretreatment agent is prepared: carboxymethyl chitosan is activated on the surface through NHS / EDC, and then reacts with phosphoethanolamine to obtain the pretreatment agent; secondly, a pyrite sample is crushed into particles, and is fully ground into powder together with NaOH, NaNO3 and the pretreatment agent; then, the temperature is increased to 180-250 DEG C and then to 350-450 DEG C for heat preservation; the sintered solid is transferred into a beaker, hot nitric acid solution is added, ultrasonic is used to dissolve the solid, and after cooling, filtration is carried out into a volumetric flask, and dilute nitric acid is used for constant volume to obtain a sample to be tested. The treatment method avoids the use of a large amount of concentrated acid and perchloric acid, the reagent consumption is small, and the method is environment-friendly; the treated sample is determined by an ICP-MS instrument and the like, and the recovery rate can be ensured to be above 95%; compared with a standard value, the RSD value is not more than 5%, and the accuracy is good.

The invention discloses a cationic immune liposome dry powder inhaler as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The cationic immune liposome dry powder inhaler disclosed by the invention is prepared from siRNA (small interfering Ribonucleic Acid) used for KRAS mutation, (2, 3-dioleyloxypropyl)-trimethyl ammonium chloride, dipalmitic acid phosphatidylcholine, cholesterol, 1, 2-distearoyl-SN-glycerol-3-phosphorylethanolamine-N-maleimide-polyethylene glycol 2000, palbolizumab and a freeze-drying protective agent. The composition is prepared through a freeze-drying process. The preparation method of the dry powder inhaler comprises the following steps: preparing the cationic liposome carrying the siRNA, preparing the cationic immune liposome coupled with the antibody, and freeze-drying the dry powder inhaler. Compared with a traditional administration mode, the inhalant has the advantages of being simple in preparation process, good in drug stability, high in targeting performance, obvious in-vivo distribution advantage and the like, and a new strategy is provided for treatment of the non-small cell lung cancer.

The invention provides a metabolic biomarker for diagnosing systemic lupus erythematosus and application of the metabolic biomarker, and belongs to the technical field of biological medicines. The metabolic biomarker is at least one metabolite of sasol, ceramide phosphate and homoveratric acid. A reagent for detecting the expression quantity of the metabolic biomarker can be used for preparing a product for diagnosing systemic lupus erythematosus. The invention determines that the expression quantities of metabolites such as 1-stearoyl-2-hydroxy-sn-glycerol-3-phosphoethanolamine, sasol, ceramide phosphate, homoveratric acid and the like in blood samples of an SLE patient and a healthy person have significant changes, so that the metabolite is put forward to be used as a biomarker for SLE disease diagnosis independently or in combination; the kit has the advantages of high accuracy, high sensitivity and high specificity, and provides a new target for diagnosis, intervention improvement and the like of SLE patients.

The application provides a metabolic marker combination for early kidney cancer diagnosis and application thereof, and belongs to the technical field of in vitro diagnosis. The metabolic marker combination for early kidney cancer diagnosis comprises a first combination or a second combination. The first combination comprises glycyl-L-glutamic acid, L-glutamyl-L-serine, methylphosphatidylcholine 33:2e and triglyceride 54:7. The second combination comprises glycyl-L-glutamic acid, L-glutamyl-L-serine, L-threonyl-L-aspartic acid, iminodiacetic acid, triglyceride 56:8, O-phosphoethanolamine, methylphosphatidylcholine 33:2e and triglyceride 54:7. By detecting the metabolic marker combination in a blood sample, it can be determined whether a patient has early kidney cancer, has high sensitivity and specificity, can realize precise screening of early kidney cancer, and provides important help for prevention and reduction of the incidence of kidney cancer.

The invention belongs to the technical field of food engineering, discloses a method for improving the preparation efficiency of a starch ester compound, and particularly relates to application of GSDL lipase OsGLIP11 in preparation of the starch ester compound. The invention discloses an amino acid sequence of OsGLIP11, which is shown in an ST.26 standard sequence nucleotide or amino acid sequence table. The starch is rice starch, and the lipid is 1, 2-dioleoyl-sn-glycerol-3-phosphorylethanolamine (DOPE) and 1, 2-distearoyl-sn-propyltriyl-3-phosphatidyl ethanolamine (DSPE), and the lipid is one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or By applying more active GDSL lipase OsGLIP11, the content of a starch ester compound formed by rice starch, DOPE and DSPE can be remarkably increased. According to the method disclosed by the invention, the GDSL lipase OsGLIP11 is added, so that the starch interacts with the exogenous lipid to generate the starch lipid compound more easily. The method can provide a theoretical reference for increasing the content of the resistant starch in the rice and further improving the digestion characteristic of the rice, and the high-resistant starch rice suitable for diabetics to eat is created.

The application discloses a combined immunization drug, a temperature-sensitive gel composition, a chemotactic factor particle and application thereof, and uses a mixed solution of an injectable temperature-sensitive polymer PLGA-PEG-PLGA, a chemotactic factor particle and an immune checkpoint inhibitor PD-1 monoclonal antibody to form a temperature-sensitive hydrogel beside a solid tumor at body temperature, and long-term controllable release of the chemotactic factor and aPD1, so as to enhance the targeting of adoptive T cells to the solid tumor and the resistance to immunosuppression in the tumor microenvironment. Through combination of the immunoregulatory temperature-sensitive gel and a tumor-penetrating peptide iRGD, the infiltration of the adoptive T cells to the solid tumor is enhanced, so that the solid tumor is efficiently treated. The chemotactic factor particle is constructed by using a distearoyl phosphoethanolamine-polyethylene glycol-N-hydroxysuccinimide modified chemotactic factor and an albumin carrier.

A use of gut microbiota or a metabolite thereof and / or an antibody or a derivative thereof in preparation of immunotherapeutic drugs for colorectal cancer. The gut microbiota comprises at least one of Alistipes shahii, Butyricimonas virosa, Desulfovibrio piger, Actinomyces humiferus, Odoribacter splanchnicus, Faecalibacterium prausnitzii, Phocaeicola plebeius, Eubacterium rectale, Oscillospiraceae bacterium, and Alistipes onderdonkii. The metabolite of the gut microbiota comprises at least one of O-phosphorylethanolamine, 5,6-dihydroxyindole-2-carboxylic acid, phosphatidylcholine (O-16:0_20:4), and 4-acetamidobutyric acid. The antibody comprises an IL-17A signaling pathway monoclonal antibody and / or a colorectal cancer-targeted monoclonal antibody.

The invention provides a nucleic acid medicinal preparation for treating hepatocellular carcinoma as well as a preparation method and application thereof, and belongs to the technical field of nucleic acid medicines. The invention provides a nucleic acid delivery carrier, which is prepared by compounding a neutral cytidine lipid material DNCA, a cystine skeleton cationic lipid material CLD and an auxiliary lipid material 1, 2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol DSPE-PEG according to a specific proportion. The invention also provides a nucleic acid medicine for treating hepatocellular carcinoma. The nucleic acid medicine comprises a nucleic acid delivery carrier, siRNA which is wrapped in the nucleic acid delivery carrier and is targeted to IGF1RmRNA, and a cell transfection solution. The nucleic acid medicine can efficiently target subcutaneous tumor parts of mouse hepatocytes, remarkably inhibits tumor growth and is free of liver and kidney toxicity. According to the technical scheme, a foundation is laid for wide clinical application of siRNA drugs for resisting hepatocellular carcinoma.

The present disclosure relates to the production of oligosaccharides, especially Human milk Oligosaccharides (HMOs) using a genetically engineered cell which has decreased or total loss of function of phosphoglycerol transferase I and II and / or phosphoethanolamine transferase and / or glucans biosynthesis protein C to reduce oligosaccharide by-products and / or increase oligosaccharide production.

The invention discloses a nano converter for inducing pyroptosis of cells as well as a preparation method and application of the nano converter. The nano converter is prepared from the following raw materials: an energy donor, a photosensitizer, cholesterol oxidase and maleimide-1, 2-distearoyl-sn-glycerol-3-phosphoethanolamine-poly (ethylene glycol) (Mal-DSPE-PEG). In the nano converter, bisoxalate and chlorin e6 form a nano micelle with Mal-DSPE-PEG through hydrophilic and hydrophobic interaction, and cholesterol oxidase reacts with maleimide to be modified on the surface of the nano micelle. The nano converter can effectively convert cholesterol and hydrogen peroxide in tumor senescence cells into singlet oxygen to finally cause pyroptosis of the tumor senescence cells. The nano converter disclosed by the invention has the advantages of universality and high safety due to targeting of metabolic characteristics generally existing in tumor senescence cells. In addition, the nano converter utilizes chemical energy to drive photodynamic therapy, and possibly existing phototoxicity is reduced due to the fact that the nano converter does not depend on an external light source.

The application belongs to the technical field of feed additives, and particularly relates to application of cytidine diphosphate ethanolamine in preparation of products for promoting animal growth or improving animal muscle performance. The application obtains the key metabolite cytidine diphosphate ethanolamine related to animal muscle performance through multi-omics joint analysis screening, the key metabolite cytidine diphosphate ethanolamine is derived from an animal body, is a key intermediate in phosphatidylethanolamine (PE) biosynthesis, and participates in CDP-Etn pathway regulation. The cytidine diphosphate ethanolamine can be applied in feed, feed additives or health products in a specific adding mode and dose, is suitable for various breeding animals such as rodents, poultry and mammals, and can significantly improve average daily feed intake, body weight growth rate, increase chest muscle weight, improve chest muscle rate and enhance grip strength.

The present invention is directed to a method for detecting the presence or absence of a bacterium resistant to a cyclic cationic polypeptide antibiotic, comprising: (a) subjecting a test sample to mass spectrometry analysis and generating a mass spectrum output; wherein said test sample comprises a bacterial membrane or a fragment thereof, wherein the fragment comprises a non-Lipid A component; (b) identifying in said mass spectrum output a first defined peak indicative of the presence of Lipid A modified by phosphoethanolamine, wherein said first defined peak is a peak present in a mass spectrum output for Lipid A modified by phosphoethanolamine and wherein said first defined peak is absent from a corresponding mass spectrum output for native Lipid A; and (c) wherein the presence of said first defined peak indicates the presence of a bacterium resistant to a cyclic cationic polypeptide antibiotic, and wherein the absence of said first defined peak indicates the absence of a bacterium resistant to a cyclic cationic polypeptide antibiotic. This method is also used in a screening method to identify an inhibitor of cyclic cationic polypeptide antibiotic resistance in a bacterium. The matrix solution can contain 2,5-dihydroxybenzoic acid and aids in the selective extraction, co-crystallisation and ionisation of native Lipid A and / or modified Lipid A as an integral part of a bacterial membrane.

The application provides metabolic biomarkers for diagnosing systemic lupus erythematosus and application thereof, and belongs to the technical field of biological medicine. The metabolic biomarker is at least one metabolite of sarsasurine, ceramide phosphate and high quercetin acid. A reagent for detecting the expression amount of the metabolic biomarker can be used for preparing a product for diagnosing systemic lupus erythematosus. The application determines that the expression amounts of 1-stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, sarsasurine, ceramide phosphate and high quercetin acid metabolites in blood samples of SLE patients and healthy people change significantly, so the metabolites are proposed to be used as biomarkers for diagnosing SLE diseases alone or in combination, and the biomarkers have the advantages of high accuracy, high sensitivity and high specificity, and provide new targets for the diagnosis and intervention improvement of SLE patients.

The invention provides an aqueous zinc ion battery electrolyte as well as a preparation method and application thereof, and relates to the technical field of electrolytes. The aqueous zinc ion battery electrolyte comprises zinc salt, O-phosphoethanolamine and water. O-phosphoethanolamine is added into the electrolyte, and O-phosphoethanolamine molecules not only can be preferentially adsorbed to the surface of a zinc negative electrode, but also can be subjected to an electrochemical decomposition reaction to form an organic-inorganic hybrid interface protection layer, so that direct contact between water molecules and the zinc negative electrode is prevented, and generation of negative electrode interface side reaction and growth of zinc dendrites are inhibited; the stability of a negative electrode interface is enhanced.

A lipid nanoparticle and a method of delivering a nucleic acid encapsulated in the lipid nanoparticle to a cell or a subject. The lipid nanoparticle may contain 55-65 mol% of a cationic lipid to the total lipid amount of the lipid nanoparticle; 30-40 mol% of a sterol to the total lipid amount of the lipid nanoparticle; 1-3 mol% of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) to the total lipid amount of the lipid nanoparticle; and 1-5 mol% of 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol (DMG-PEG) to the total lipid amount of the lipid nanoparticle. The lipid nanoparticle may also contain 55-65 mol% of a cationic lipid to a total lipid amount of the lipid nanoparticle; 30-40 mol% of a sterol to the total lipid amount of the lipid nanoparticle; 4-6 mol% of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) to the total lipid amount of the lipid nanoparticle; and 1-5 mol% of 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol (DMG-PEG) to the total lipid amount of the lipid nanoparticle.